Advertisement
Screener

FATE THERAPEUTICS INC (FATE) Preferred Stock, Shares Outstanding

2.8 / 5 stars · 68/120 Roast Me

FATE THERAPEUTICS INC Preferred Stock, Shares Outstanding

FATE THERAPEUTICS INC (FATE) had Preferred Stock, Shares Outstanding of 2.76 million shares as of 2024-06-30, per its 10-Q filed 2024-08-13.

Discontinued › Balance Sheet › Equity › Preferred Stock, Number of Shares, Par Value and Other Disclosure

us-gaap:PreferredStockSharesOutstanding · last filed 2024-08-13

  • 2024-06-30: Preferred Stock, Shares Outstanding 2.76M shares.
  • 2023-12-31: Preferred Stock, Shares Outstanding 2.76M shares.
  • 2016-09-30: Preferred Stock, Shares Outstanding 0.00 shares.
  • 2016-06-30: Preferred Stock, Shares Outstanding 0.00 shares.
Period endPreferred Stock, Shares Outstanding
2024-06-302.76M shares
10-Q · filed 2024-08-13
2023-12-312.76M shares
10-Q · filed 2024-08-13
2016-09-300.00 shares
10-Q · filed 2016-11-07
2016-06-300.00 shares
10-Q · filed 2016-08-08
2016-03-310.00 shares
10-Q · filed 2016-05-09
2015-12-310.00 shares
10-Q · filed 2016-11-07
2015-09-300.00 shares
10-Q · filed 2015-11-03
2015-06-300.00 shares
10-Q · filed 2015-08-05
2015-03-310.00 shares
10-Q · filed 2015-05-07
2014-12-310.00 shares
10-K · filed 2016-03-03
2014-09-300.00 shares
10-Q · filed 2014-11-12
2014-06-300.00 shares
10-Q · filed 2014-08-12
2014-03-310.00 shares
10-Q · filed 2014-05-13
2013-12-310.00 shares
10-K · filed 2015-03-12
2012-12-310.00 shares
10-K · filed 2014-03-17

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35